MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study

Sponsor
Linkoeping University
Study ID
NCT07312136
Status
Enrolling By Invitation

Conditions

  • Advanced Fibrosis
  • Cirrhosis
  • Hypertension
  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Metabolic Syndrome
  • OSAS (Obstructive Sleep Apneas Syndrome)
  • Obesity & Overweight
  • Sarcopenia
  • Type 2 Diabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The EPSOMIP2 (Evaluating the Prevalence and Severity Of MASLD In Primary care - a Follow-up Study) trial is a longitudinal cohort study of patients with type 2 diabetes recruited from primary health care centers in Östergötland, Sweden. Between 2019-2023, 317 patients were included and underwent rigorous clinical evaluation, vibration controlled transient elastography, biobanking of bloodsamples, and the latest magnetic resonance techniques to liver and body composition. All patients alive will be re-invited to undergo the same evaluation and additional tests.

Key Dates

First listed
Dec 31, 2025
Start date
Dec 16, 2025
Status verified
Dec 2025
Primary completion
Dec 31, 2031
Completion
Dec 31, 2034

Study Design

Enrollment
317 participants (estimated)

Primary Outcome Measure

Prevalence of MASLD [ Time Frame: 2031 ]

Find similar trials

Nationwide
Hypertension (high blood pressure) trialsType 2 diabetes trialsCardiology trialsHeart disease trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies